Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $18.3 Million - $20.3 Million
-215,210 Reduced 87.03%
32,070 $2.84 Million
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $2.18 Million - $2.53 Million
-25,180 Reduced 9.24%
247,280 $21.4 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $1.22 Million - $1.64 Million
-13,950 Reduced 4.87%
272,460 $26.5 Million
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $825,486 - $1.11 Million
10,200 Added 3.69%
286,410 $29.6 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $4.72 Million - $5.57 Million
57,430 Added 26.25%
276,210 $23.4 Million
Q1 2022

May 11, 2022

SELL
$74.28 - $92.69 $788,853 - $984,367
-10,620 Reduced 4.63%
218,780 $16.9 Million
Q4 2021

Feb 11, 2022

SELL
$71.72 - $91.47 $97,539 - $124,399
-1,360 Reduced 0.59%
229,400 $20.3 Million
Q3 2021

Nov 05, 2021

BUY
$74.77 - $85.47 $1.31 Million - $1.5 Million
17,580 Added 8.25%
230,760 $17.8 Million
Q2 2021

Aug 13, 2021

SELL
$75.51 - $84.79 $655,426 - $735,977
-8,680 Reduced 3.91%
213,180 $17.8 Million
Q1 2021

May 07, 2021

BUY
$74.73 - $90.69 $570,937 - $692,871
7,640 Added 3.57%
221,860 $16.8 Million
Q3 2020

Nov 16, 2020

BUY
$71.87 - $131.03 $518,182 - $944,726
7,210 Added 3.48%
214,220 $16.3 Million
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $2.89 Million - $4.52 Million
-36,370 Reduced 14.94%
207,010 $25.5 Million
Q1 2020

May 15, 2020

BUY
$71.37 - $96.85 $17.4 Million - $23.6 Million
243,380 New
243,380 $20.6 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Nippon Life Global Investors Americas, Inc. Portfolio

Follow Nippon Life Global Investors Americas, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nippon Life Global Investors Americas, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nippon Life Global Investors Americas, Inc. with notifications on news.